MustGrow Biologics (CSE: MGRO) is progressing with field trials for its TerraMG product. The company announced this morning that it has entered into an agreement for collaborative field trials for the product with that of NexusBioAg, a division of Univar Solutions (NYSE: UNVR).
The collaboration will see NexusBioAg conduct field trials of the firms mustard-derived biopesticide known as TerraMG, with field trials focused on clubroot and aphanomyces disease. More specifically, field trials to test the product against these diseases will be conducted on canola and pulse crops respectively.
NexusBioAg is to conduct the field trials, while MustGrow provides scientific support as well as the product for testing. Field trial tests follow successful greenhouse tests conducted last year by the company, wherein 96.1% disease control at an application rate of 0.5 gallons per acre, and 98.5% control at a rate of 10 gallons per acre was recorded against clubroot. In January meanwhile, the company reported 100% control of aphanomyces, the pathogen responsible for root rot, within laboratory testing.
“MustGrow’s R&D team has developed a sustainable farming solution to address the agronomic challenges of treating Clubroot and Aphanomyces. We are excited to add TerraMG to our field trial program to further demonstrate that TerraMG is complementary to the NexusBioAg portfolio.”
Daniel Samphir, NexusBioAg Marketing Manager
MustGrow Biologics last traded at $1.74 on the CSE.
Sponsored · Cambria Gold Mines
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
